Henry Schein, Inc. (HSIC) vs Xeris Biopharma Holdings, Inc. (XERS)
The same free fields, in the same order, for both companies, so a figure on one line can be read straight across.
This page states measurements and nothing else. It does not rank the two companies, name one of them, or draw a conclusion from the figures.
Data as of Oct 27, 2026, for both companies.
The figures, field by field
A dash means the snapshot carries no figure for that company on that line. A line is dropped only when neither company has it, so a dash beside a figure is a fact about coverage, not about either company.
| HSIC | XERS | |
|---|---|---|
| Sector | Healthcare | Healthcare |
| Industry | Medical Distribution | Drug Manufacturers - Specialty & Generic |
| Size band | MID | SMALL |
| Listing | Nasdaq GS | Nasdaq GS |
| Country | United States | United States |
| Theme | dental-care | rare-disease |
| Price and returns | ||
| Last close | $84.51 | $10.21 |
| Return · 1 week | +0.64% | −6.76% |
| Return · 1 month | −1.72% | +3.87% |
| Return · 3 months | −1.40% | +23.91% |
| Return · year to date | +10.01% | +38.91% |
| Return · 1 year | +33.00% | +9.67% |
| Distance from the 52-week highThe last close measured against the highest close of the past 52 weeks. | −8.32% | −10.60% |
| 52-week high | $92.18 | $11.42 |
| 52-week low | $62.15 | $5.25 |
| Size and turnover | ||
| Market value · USDConverted to US dollars, so two companies listed in different currencies sit under one heading. | $9.63B | $1.86B |
| Turnover · median day, USDThe median value traded in a session over the past 50 sessions. | $86.83M | $19.85M |
| Employees | 25,000 | 435 |
| Valuation | ||
| Price to earnings · trailing | 24.77× | n/a (negative earnings) |
| Price to earnings · forward | 14.17× | 51.86× |
| Price to sales | 0.71× | 5.54× |
| Price to book | 3.01× | n/a (negative book value) |
| Enterprise value to EBITDA | 13.60× | 41.57× |
| Enterprise value to revenue | 1.08× | 6.04× |
| PEG ratio | 1.69 | — |
| Earnings per share · trailing | 3.43 | -0.09 |
| Profitability | ||
| Gross margin | 31.32% | 86.58% |
| Operating margin | 5.76% | 5.62% |
| Profit margin | 2.96% | −5.12% |
| Return on equity | 8.85% | — |
| Return on assets | 4.39% | 6.13% |
| Growth | ||
| Revenue growth | +6.70% | +28.70% |
| Earnings growth | +17.10% | — |
| Balance sheet and payout | ||
| Debt / equity (%) | 80.73 | — |
| Current ratio | 1.32 | 1.45 |
| Dividend yield | 0.00% | 0.00% |
| Payout ratio | 0.00% | 0.00% |
| Trend and volatility | ||
| RSI · 14 | 45.66 | 60.03 |
| ADX · 14 | 18.77 | 17.69 |
| 50-day average | $86.85 | $8.34 |
| 200-day average | $80.89 | $7.10 |
| Average true range · share of priceAverage true range over 14 sessions, stated as a share of the last close, so it can be read across two share prices. | 2.39% | 3.99% |
The full HSIC analysis
Everything this table leaves out for Henry Schein, Inc.: the plain-language summary and key points, the accumulation read, signal history, full fundamentals, market context, and the case each side of the HSIC argument makes.
$9.90 per stock, one time, 30 days of access.
Open the full HSIC analysisThe full XERS analysis
Everything this table leaves out for Xeris Biopharma Holdings, Inc.: the plain-language summary and key points, the accumulation read, signal history, full fundamentals, market context, and the case each side of the XERS argument makes.
$9.90 per stock, one time, 30 days of access.
Open the full XERS analysis